Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

SGX:T14 Revenue

Tianjin Pharmaceutical Da Ren Tang Group Corporation had revenue of 1.20B CNY in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to 5.99B, down -26.01% year-over-year. In the year 2024, Tianjin Pharmaceutical Da Ren Tang Group Corporation had annual revenue of 7.31B, down -11.14%.

• Revenue (ttm): 5.99B CNY
• Revenue Growth: -26.01%
• P/S Ratio: 4.93
• Revenue / Employee: 1.30M CNY
• Employees: 4,619
• Market Cap: 5.25B SGD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	7.31B	-915.58M	-11.14%
Dec 31, 2023	8.22B	-26.94M	-0.33%
Dec 31, 2022	8.25B	1.34B	19.42%
Dec 31, 2021	6.91B	303.89M	4.60%
Dec 31, 2020	6.60B	-390.23M	-5.58%